Narrative
发表于 2025-3-26 23:19:10
Immunoconjugate Anticancer Therapeuticse “dock-and-lock” (DNL) technology enables the facile assembly of multifunctional structures of defined composition, combining the targeting and the therapeutic moieties site specifically. Recent advances in the use of different classes of immunoconjugates are described.
cardiovascular
发表于 2025-3-27 01:48:18
http://reply.papertrans.cn/63/6211/621043/621043_32.png
Graduated
发表于 2025-3-27 06:50:50
http://reply.papertrans.cn/63/6211/621043/621043_33.png
Ischemia
发表于 2025-3-27 12:32:44
Monoclonal Antibody Therapy for Hematologic Malignanciesmphomas in the Western world, is rituximab combined with chemotherapy. Second-generation anti-CD20 monoclonal antibodies are currently being studied in phase II and III trials. Radioimmunotherapy with anti-CD20 antibodies has also been approved by the FDA for the second-line treatment of follicular
CYN
发表于 2025-3-27 14:00:28
http://reply.papertrans.cn/63/6211/621043/621043_35.png
AGONY
发表于 2025-3-27 18:22:45
http://reply.papertrans.cn/63/6211/621043/621043_36.png
和平主义者
发表于 2025-3-28 00:57:34
http://reply.papertrans.cn/63/6211/621043/621043_37.png
detach
发表于 2025-3-28 03:13:30
http://reply.papertrans.cn/63/6211/621043/621043_38.png
Anthology
发表于 2025-3-28 08:32:28
http://reply.papertrans.cn/63/6211/621043/621043_39.png
向外供接触
发表于 2025-3-28 10:55:12
http://reply.papertrans.cn/63/6211/621043/621043_40.png